July 14, 2023
Robbins Geller Rudman & Dowd LLP attorneys who represent a class of McKesson investors will receive $35 million in fees from a $141 million settlement for their work on litigation alleging the company made false assertions concerning a drug price-fixing scheme, according to an order issued in California federal court on Friday.
November 04, 2022
McKesson will pay shareholders $141 million to resolve class action claims in federal court in California over its allegedly false assertions about generic drug prices that plaintiffs traced to a generic-drug price-fixing conspiracy, according to an investor filing.
October 21, 2021
A California federal judge appeared inclined Thursday to grant McKesson summary judgment on some securities fraud claims over its alleged participation in a generic drug price-fixing scheme, asking repeatedly what difference it would make to shareholders if they knew McKesson's artificial prices were caused by anti-competitive conduct and not inflation.
October 30, 2019
McKesson Corp. must face securities fraud claims over its alleged participation in an industry-wide generic drug price-fixing scheme, a California federal court ruled Wednesday, denying the drug wholesaler's bid to escape the suit.
October 18, 2019
A California federal judge appeared skeptical Friday of McKesson Corp.'s bid to toss investors' claims that they were misled as part of its alleged participation in an industry-wide conspiracy to drive up generic drug prices, saying the proposed class had adequately stated that the drug company's alleged lies caused them harm.